Eli Lilly Nederland B.V. is the Dutch subsidiary of Eli Lilly and Company, one of the world's leading pharmaceutical companies headquartered in Indianapolis, United States. Established in the Netherlands since 1976, the company is registered with the Dutch Chamber of Commerce under KvK number 30087090 and is based in Utrecht.
Its main activities include the import, export, distribution, and marketing of pharmaceutical, veterinary, and diagnostic products. The subsidiary also engages in clinical research, sales support, and healthcare services for patients and providers. With around 100 employees, it focuses on key therapeutic areas such as diabetes and obesity, oncology, immunology, and neurology, including Alzheimer's disease.
Eli Lilly Nederland B.V. acts as the marketing authorization holder for numerous EU centrally authorized medicines, including blockbuster products like Mounjaro (tirzepatide) for diabetes and weight management, Trulicity (dulaglutide), Verzenios (abemaciclib) for cancer, and Omvoh (mirikizumab) for immunology. It was identified as the applicant for Foundayo (orforglipron), a novel oral GLP-1 receptor agonist for weight management and type 2 diabetes.
The company is owned by the Eli Lilly group through Lilly Nederland Holding B.V. In a significant expansion, it is investing €2.6 billion in a new advanced manufacturing facility in Katwijk, Netherlands, to boost European production capacity and create hundreds of jobs. This positions the subsidiary as an important hub for Lilly's European operations within a global network spanning over 110 countries.
As part of Eli Lilly and Company, which pioneered insulin production and continues to lead in innovative medicines with substantial R&D investment, Eli Lilly Nederland B.V. supports the group's mission to improve lives through science-based pharmaceuticals.
Also known as Lilly Nederland B.V. and Eli Lilly Nederland BV.
None yet. When a new project in the record names Lilly Nederland as owner, partner or investor, it shows here.
Oral orforglipron showed 5–11% weight loss at 72 weeks and 1.2–1.9 percentage‑point HbA1c reductions; CHMP opinion now goes to the European Commission for an EU licence.
